Literature DB >> 30872045

Antagonists of TNFα for recurrent miscarriages: 2 Illustrative cases.

Arsène Mekinian1, Véronique Houfflin-Debarge2, Kamilla Kolanska3, Jonathan Cohen3, Noémie Abisror4, Marie Bornes3, Gilles Kayem5, Olivier Fain4.   

Abstract

Approximately 1 to 3% of women have recurrent early miscarriages, defined as ≥3 pregnancy losses before 14 weeks of gestation. The immune deregulation and tolerance rupture could be the origin of these miscarriages in at least 30% of these women. Chronic intervillositis of unknown etiology (CIUE) is a rare placental lesion characterized by intrauterine deaths, growth restriction and high recurrence rate. In cases with recurrent obstetrical adverse events and intrauterine deaths, we previously reported the benefit of hydroxychloroquine combination to prednisone. Even few data raised the potential value of TNF antagonists in early recurrent miscarriages, these cases show its potential value in the setting of recurrent refractory chronic intervillositis and unexplained miscarriages.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adalimumab; Chronic intervillositis; Miscarriages; Outcome

Mesh:

Substances:

Year:  2019        PMID: 30872045     DOI: 10.1016/j.ejogrb.2019.02.036

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  3 in total

Review 1.  Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome.

Authors:  Emily F Cornish; Thomas McDonnell; David J Williams
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

2.  Immunomodulatory Therapy Reduces the Severity of Placental Lesions in Chronic Histiocytic Intervillositis.

Authors:  Chloe A Brady; Charlotte Williams; Gauri Batra; Elaine Church; Clare L Tower; Ian P Crocker; Alexander E P Heazell
Journal:  Front Med (Lausanne)       Date:  2021-10-18

3.  Chronic histiocytic intervillositis (CHI): current treatments and perinatal outcomes, a systematic review and a meta-analysis.

Authors:  Laurel Moar; Chloe Simela; Surabhi Nanda; Andreas Marnerides; Mudher Al-Adnani; Catherine Nelson-Piercy; Kypros H Nicolaides; Panicos Shangaris
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.